At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Rifampicin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Rifampicin on the Pharmacokinetics of BI 425809 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)
In Brief
A Phase 1 clinical trial evaluating Rifampicin and BI 425809 for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The primary objective of this trial is to investigate the relative bioavailability of a single dose of BI 425809 when given alone (Reference, B) compared with co-administration (Test, A) on the 7th day of a 10-day treatment with rifampicin following oral administration in healthy male volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionJun 2017
TodayJul 2026
First PostedMar 17, 2017
Enrollment StartMar 28, 2017
Primary CompletionJun 20, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.3 years ago
Interventions
Rifampicindrug
once daily
BI 425809drug
once daily